Ocular Therapeutix expects top-line data from OTX-TP's first Phase III glaucoma study in the first half of 2019, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes investors have discounted this program based on mixed Phase I/II data that utilized different formulations and study designs. However, he thinks the Phase III design gives OTX-TP the best chance at demonstrating clinical efficacy in this setting. A successful outcome will be statistically significant IOP-reductions over placebo at all time points and importantly, at least a 5 mm Hg reduction in IOP from baseline at 6 of the 9 time points, Catanzaro contends, citing his review of literature and a survey of ophthalmologists. He believes such an outcome would represent "another successful application of the hydrogel platform and drive significant share appreciation." The analyst has an Overweight rating on Ocular Therapeutix with a $14 price target.